comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 21:27:13 - browse：77999

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Novo Nordisk to expand supply of Wegovy for U.S. patients

explore

WSS

WHO calls for emergency meeting on new China virus, as cases spread

Group opposing PBM reform sets lobbying record

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

How Medicaid coverage policies for immigrants impact new moms

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Why hospitals are withdrawing from US News rankings

entertainment

comprehensive

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Time to name cancers by genetics, not organ of origin, expert says

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Covid misinformation case heads to Supreme Court

ChatGPT in medicine: STAT answers readers' burning questions

How Medicaid coverage policies for immigrants impact new moms

Novavax promises a turnaround & Lilly roils the obesity market

ARCH Venture Partners is raising $3 billion for a life sciences fund

In Memoriam: Notable people who died in 2023

Google and Epic fight stronger regulation of AI in health care

explore

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Woodcock on FDA’s accelerated approval and her next chapter

General Catalyst, Summa Health deal will turn on physician buy

Medicare drug price negotiation’s day in court

Doctors find melanoma drugs effective against rare brain cancer

As digital health tech proliferates, a new institute aims to cut through hype

Wikipedia

explore

knowledge

explore